Introduction {#s1}
============

Macroautophagy, referred to hereafter as autophagy, is a cellular process by which proteins and organelles are degraded and recycled through sequestration within autophagosomes and delivery to lysosomes ([@bib35]). The autophagy pathway is highly conserved and required for organismal development and function. Defects in autophagy are associated with diseases including cancer, metabolic disruption, and neurodegenerative disorder ([@bib10]; [@bib11]; [@bib17]). Patients with mutations in any of the non-redundant core autophagy-related (*ATG*) genes have not previously been reported.

Ataxia is a neurodegenerative disease caused by disruption of the cerebellum and Purkinje cells, which results in the lack of coordinated muscle movements. Large phenotype diversity is present in individuals with ataxia, including age of onset, rate of progression, and other accompanying neurological and non-neurological features ([@bib26]), with corresponding genotypic heterogeneity ([@bib52]). Even within the more defined phenotype of childhood ataxia with developmental delay, there are a large number of associated genes, such that similar phenotypic features alone are often insufficient information for an accurate diagnosis ([@bib5]; [@bib12]; [@bib26]). Identification of genetic causes of childhood ataxia is important for understanding disease pathogenesis and for possible future treatment development.

Whole exome sequencing has been successfully utilized to identify known and novel genetic mutations responsible for ataxia ([@bib5]; [@bib16]). Identification of candidate genes can be further verified through additional molecular analysis and utilization of specific and general animal models. Here we identified a novel mutation in a core autophagy gene, *ATG5*, in two children with ataxia, and demonstrate a reduction in autophagic response, also reproducing the phenotype in yeast and fly models.

Results {#s2}
=======

E122D mutation in ATG5 is associated with familial ataxia {#s2-1}
---------------------------------------------------------

Two Turkish siblings presented with ataxia and developmental delay in childhood, as previously described ([@bib59]). We performed linkage analysis on both affected siblings, their unaffected siblings, and their unaffected mother, using a model of remote parental consanguinity and identified a single broad (\>14 Mbp) peak with LOD score 3.16 on chromosome 6q21, between 102 and 116 Mb ([Figure 1](#fig1){ref-type="fig"}). Whole exome sequencing identified a homozygous missense mutation, hg19 chr6:106,727,648 T\>A, corresponding to E122D in *ATG5* ([Figure 2A](#fig2){ref-type="fig"}) as the only damaging mutation within the genetically identified chromosomal linkage interval. The mutation was Sanger verified and found absent from variant databases and from Turkish controls.10.7554/eLife.12245.003Figure 1.Linkage analysis in consanguineous family with two siblings with ataxia, mental retardation and developmental delay maps defect to chromosomal interval containing *ATG5*.Remote consanguinity was detected between parents of two previously described siblings having ataxia ([@bib59]), illustrated here as third cousins. SNP and linkage results for chromosome 6 (**B**) are illustrated below the pedigree (**A**). The shared homozygous region lies between rs4334996 and rs1204817, encompassing ATG5 at 106.6 Mb. Father (501)'s alleles were inferred, 0 denotes unknown alleles. Affected siblings, 601 and 602, are denoted by black squares and unaffected family members by open symbols. The proximal boundary is defined by a recombination event between rs1547384 and rs4334996 in affected individual 602, while the distal boundary is defined as an ancestral recombination event (lack of homozygosity, dark green) between rs1204817 and rs648248. Orange arrows indicate the position of *ATG5.***DOI:** [http://dx.doi.org/10.7554/eLife.12245.003](10.7554/eLife.12245.003)10.7554/eLife.12245.004Figure 2.The primary sequence of ATG5, including the mutant E122 residue, as well as the protein structure is highly conserved across eukaryotic species.(**A**) Amino acid sequence alignment between ATG5 orthologs from human (HsaATG5), mouse (MmuAtg5), *Drosophila melanogaster* (DmeAtg5) and *Saccharomyces cerevisiae* (SceAtg5) was constructed at GenomeNet (Kyoto University Bioinformatics Center) through CLUSTALW and rendered in Genedoc v.2.7 using default settings. E122 in human ATG5 and E141 in yeast Atg5, which are homologous residues, are indicated by red arrows. (**B**) Location of E122 residue is highlighted in yellow on the crystal structure of a human ATG12 (residues 53--140)--ATG5 -ATG16L1 (residues 11--43) complex (PDB ID: 4NAW). ATG5 is shown in cyan, ATG16L1 in magenta, and ATG12 in green ([@bib47]). (**C**) Location of the E141 residue in yeast Atg5, which corresponds to the E122 in human ATG5, is indicated in yellow on the crystal structure of a yeast Atg12 (100--186)--Atg5 -Atg16 (1--46) complex, colored as for the human counterparts as in panel B (PDB ID: 3W1S) ([@bib46]). (**D**) Superimposition of crystal structure of ATG5^E122D^-ATG16L1 with ATG5^WT^-ATG16L1 (PDB: 4TQ0) ([@bib29]). Close-up view of ATG5 structure around WT (**E**) and E122D (**F**) mutation.**DOI:** [http://dx.doi.org/10.7554/eLife.12245.004](10.7554/eLife.12245.004)

Cells from ATG5^E122D/E122D^ patients exhibit reduced ATG12--ATG5 expression {#s2-2}
----------------------------------------------------------------------------

ATG5 plays a role in elongation of the phagophore and its subsequent maturation into the complete autophagosome. ATG12 is a ubiquitin-like protein that covalently binds ATG5 ([@bib40]), and this conjugate noncovalently binds ATG16L1. Crystal structure of the resulting ATG12--ATG5-ATG16L1 complex indicated that E122 is located in the vicinity of the ATG12--ATG5 interaction surface ([Figure 2B](#fig2){ref-type="fig"}); hence, we predicted that the mutation in ATG5 could affect the conjugation of ATG12. Comparison of protein isolated from control lymphoblastoid cell lines (LCL) and of affected subjects revealed a severe reduction of the ATG12--ATG5 conjugate in the mutant cells under basal conditions ([Figure 3A](#fig3){ref-type="fig"}), suggesting that the E122D mutation may have impaired autophagy by inhibiting conjugation between ATG12 and ATG5.10.7554/eLife.12245.005Figure 3.Cells from ataxia patients with *ATG5^E122D/E122D^ *mutation exhibit autophagy defects.(**A**) Decreased expression of ATG12--ATG5 conjugates in cells from ataxia patients with *ATG5^E122D/E122D^* mutation. ATG5 immunoblotting (IB) of ATG12--ATG5 conjugates of LCLs from individuals whose *ATG5* genotype corresponds to wild type (A to I) or E122D (J and K). (**B**) Decreased autophagic flux in *ATG5^E122D/E122D^*LCL cells. A subset of LCLs from (**A**) were treated with 0.1 μM bafilomycin A~1~ (Baf) for the indicated hours and analyzed by IB. LC3-II is an autophagosome marker, and LC3-I is a precursor for LC3-II. Baf inhibits lysosomal degradation of LC3-II. Actin is shown as a loading control. (**C**) Decreased autophagic flux and increased expression of SQSTM1, an autophagy substrate, in *ATG5^E122D/E122D^*LCL cells. A subset of LCLs from (**A**) were treated with 250 nM Torin 1 or 0.1 μM Baf, for 2 hr and analyzed by IB. Torin 1 is an autophagic flux activator.**DOI:** [http://dx.doi.org/10.7554/eLife.12245.005](10.7554/eLife.12245.005)

Cells from ATG5^E122D/E122D^ patients exhibit autophagic flux attenuation {#s2-3}
-------------------------------------------------------------------------

The ATG12--ATG5-ATG16L1 complex functions in part as an E3 ligase to facilitate the conjugation of LC3 to phosphatidylethanolamine, generating LC3-II ([@bib18]; [@bib23]). Compared to control cells, LCLs from patients with the E122D mutation exposed to bafilomycin A~1~ showed a substantial reduction in LC3-II accumulation under basal conditions ([Figure 3B](#fig3){ref-type="fig"}), suggesting a possible decrease in E3 activity and subsequent attenuation of basal autophagic flux. The patient LCLs were also unable to upregulate their autophagic flux in response to Torin 1 ([Figure 3C](#fig3){ref-type="fig"}), which is a strong inducer of autophagy ([@bib56]). ATG5^E122D^ LCLs also showed elevated levels of SQSTM1/p62, an autophagy receptor and substrate, further indicating disruption of basal autophagy ([Figure 3C](#fig3){ref-type="fig"}).

E122D mutation of ATG5 impairs ATG12--ATG5 conjugation {#s2-4}
------------------------------------------------------

To examine the effect of the ATG5^E122D^ mutation on formation of the ATG12--ATG5-ATG16L1 complex, we expressed the recombinant human proteins in insect Hi5 cells and analyzed the complexes by affinity isolation. We could detect the ATG12--ATG5 complex when both wild-type proteins were co-expressed, but we could only detect a minimal amount of the ATG12--ATG5^E122D^ complex ([Figure 4A](#fig4){ref-type="fig"}). Although overexpression of human ATG5^WT^ in HEK293 cells or *Drosophila* tissues resulted in efficient covalent conjugation with overexpressed human ATG12 ([Figure 4B and C](#fig4){ref-type="fig"}) or endogenous *Drosophila* Atg12 ([Figure 4D](#fig4){ref-type="fig"}), mutant ATG5^E122D^ was dramatically impaired in this process ([Figure 4B, C and D](#fig4){ref-type="fig"}). Interestingly, expression levels of ATG5^WT^ and ATG5^E122D^ monomers were comparable to each other, indicating that the mutation affects the conjugation process, rather than the stability of proteins. This was consistent with the structural location of ATG5 E122 adjacent to the surface that interacts with ATG12 ([Figure 2B](#fig2){ref-type="fig"}). To confirm that the mutation does not overtly alter the structure of ATG5 or binding to ATG16L1, we analyzed formation of the noncovalent ATG5-ATG16L1 complex using constructs containing a TEV protease site. Both wild-type and mutant ATG5 protein were efficiently co-precipitated with ATG16L1 ([Figure 4E](#fig4){ref-type="fig"}). Indeed, the co-crystal structure of a human ATG5^E122D^-ATG16L1 complex ([Figure 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) superimposes well with the previously determined structure of the WT proteins ([Figure 2D](#fig2){ref-type="fig"}), with the major obvious difference being replacement of the side-chain ([Figure 2E and F](#fig2){ref-type="fig"}). Thus, it appears that the E122D mutation interferes with the ATG12--ATG5 conjugation process, but not with ATG5 folding or binding of ATG16L1.10.7554/eLife.12245.006Figure 4.E122D mutation interferes with formation of the ATG12--ATG5 conjugate.(**A**) Coomassie Blue-stained SDS-PAGE gel following glutathione affinity purification from lysates of Hi5 cells infected with baculoviruses expressing GST-ATG12 and either WT or E122D mutant ATG5. (**B** and **C**) HEK293 cells expressing the indicated proteins were analyzed by IB. (**D**) *Drosophila* whole bodies expressing the indicated transgenes under the control of *Tub-Gal4* were analyzed by IB. (**E**) Lysates from Hi5 cells expressing the indicated proteins were subjected to His/Ni-NTA purification and subsequent TEV protease treatment. Proteins were analyzed by Coomassie Blue staining.**DOI:** [http://dx.doi.org/10.7554/eLife.12245.006](10.7554/eLife.12245.006)10.7554/eLife.12245.007Table 1.Crystallography data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.12245.007](10.7554/eLife.12245.007)*Data collection*Beam lineAPS 24-ID-CSpace groupC2Unit cell parameters*a, b, c* (Å)217.1, 84.5, 151.9α, β, γ (°)90, 133.8, 90Resolution (Å) (highest shell)50--3.0 (3.12-3.0)Wavelength (Å)0.9792Number of measured reflections179,310Number of unique refections39,496Overall *R*~sym~0.057 (0.645)Completeness (%)98.9 (99.3)Overall *I*/σ*I*14.3 (2.3)Multiplicity4.5*Refinement*Resolution (Å)50--3.0*R*~work~/*R*~free~0.198/0.244rmsd bond lengths (Å)0.008rmsd bond angles (°)0.994Number of protein atoms9403*Ramachandran statistics*Preferred (%)97.69Allowed (%)2.22Disallowed (%)0.09

ATG5 mutation in yeast results in decreased autophagy {#s2-5}
-----------------------------------------------------

ATG5 is a highly conserved protein, and sequence alignment demonstrated that E122 corresponds to yeast E141 ([Figure 2A and C](#fig2){ref-type="fig"}). We extended our analysis of the effect of the mutation on autophagy activity, by taking advantage of the yeast system. To test whether autophagy was affected by the *Atg5* mutation in yeast, we initially relied on the GFP-Atg8 processing assay ([@bib55]). During autophagy a population of Atg8 is continuously transported to the vacuole inside of autophagosomes. Tagging the N terminus of Atg8 with GFP makes it possible to monitor autophagy flux because Atg8 is rapidly degraded inside the vacuole whereas GFP is relatively resistant to vacuolar hydrolases; the generation of free GFP is an indication of autophagic activity. We observed a consistent decrease in autophagy activity with the Atg5^E141D^ mutant relative to Atg5^WT^ following autophagy induction by starvation ([Figure 5A](#fig5){ref-type="fig"}). Atg8, or GFP-Atg8, does not measure autophagic cargo per se ([@bib31]), and the amount of GFP-Atg8 processing only corresponds to the inner surface of the autophagosome. To corroborate the effects observed through the GFP-Atg8 processing assay we examined autophagy using the quantitative Pho8∆60 assay ([@bib45]). Pho8∆60 is an altered form of a phosphatase that is only delivered to the vacuole via autophagy; subsequent proteolytic processing generates an active form of the hydrolase. After 4 and 6 hr of starvation, yeast cells expressing the plasmid-based Atg5^E141D^ mutant showed a significant decrease in autophagy levels compared to cells expressing Atg5^WT^ ([Figure 5B](#fig5){ref-type="fig"}), and similar results were obtained when the WT and mutant *ATG5* genes were integrated back into the chromosomal *ATG5* locus ([Figure 5C](#fig5){ref-type="fig"}).10.7554/eLife.12245.008Figure 5.E141D mutation of yeast Atg5 attenuates autophagy.(**A-D**) Yeast cells were grown in SMD to mid-log phase and nitrogen starved for the indicated times. (**A**) WLY176 *atg5∆* yeast cells expressed GFP-Atg8 through its endogenous promoter and plasmid-based Atg5^WT^-PA, Atg5^E141D^-PA or an empty vector. Protein extracts were analyzed for GFP-Atg8 processing by western blot. The ratio of free GFP to Dpm1 (loading control) is presented below the blots, and quantification is presented on the right (Student's t test, n=4; \*p \< 0.05); the value for Atg5^WT^ at 6 hr was set to 1.0 and other values were normalized. (**B**) WLY176 *atg5∆* yeast cells expressed either plasmid-based Atg5^WT^-PA, Atg5^E141D^-PA or an empty vector. Protein extracts were used to measure autophagy through the Pho8Δ60 assay (Student's t test, n=6; \*p \< 0.05). (**C**) WLY176 cells with genomic integrated Atg5^WT^ or Atg5^E141D^ were used to generate protein extracts and autophagy was monitored through the Pho8Δ60 assay (Student's t test, n=3; \*p \< 0.05). (**D**) WLY176 *atg5∆* yeast cells expressing plasmid-based Atg5^WT^-PA, Atg5^E141D^-PA or an empty vector were used to generate protein extracts. The ratio of Atg8--PE to total Atg8 is presented below the blots based on western blot using antiserum to Atg8. Dpm1 was used as a loading control. (**E**) *MKO ATG3* (YCY137) cells were co-transformed with pATG8*∆*R-ATG7-ATG10(414), and either pATG5^WT^-HA-ATG12(416), pATG5^E141D^-HA-ATG12(416), pATG5^WT^-HA-ATG12-ATG16(416), or pATG5^E141D^-HA-ATG12-ATG16(416). Overnight cultures were diluted to OD=0.02 in SMD -Ura -Trp. The cells were incubated at 30°C for 18 hr to mid-log phase before they were shifted to SD-N for nitrogen starvation. Samples at the corresponding time points were collected, TCA precipitated and subsequently analyzed by western blot. S.E., short exposure; L.E., long exposure.**DOI:** [http://dx.doi.org/10.7554/eLife.12245.008](10.7554/eLife.12245.008)

To determine the reason for reduced autophagic activity we tested the effects of the Atg5^E141D^ mutant on Atg8 lipidation. As shown by the ratio of Atg8--PE:total Atg8, cells expressing Atg5^E141D^ displayed a decrease in Atg8--PE conjugation at 30 and 60 min of starvation compared to cells expressing Atg5^WT^ ([Figure 5D](#fig5){ref-type="fig"}). We extended this analysis using the in vivo reconstitution of Atg8--PE conjugation as described previously ([@bib7]). In brief, we examined Atg8 lipidation in a multiple-knockout (MKO) strain in which 23 *ATG* genes are deleted, when expressing only the E1, E2 and E3-like conjugation enzymes of the autophagy machinery. Atg8*∆*R that lacks the C-terminal arginine was used in the assay to bypass the initial activation step initiated by Atg4; due to the absence of Atg4, there is no cleavage of Atg8--PE from the membrane, resulting in stabilization of this form of the protein. We found that the Atg5^E141D^ mutant was significantly defective in Atg8--PE conjugation compared to the cells with Atg5^WT^ when Atg16 was not present ([Figure 5E](#fig5){ref-type="fig"}). Atg16 is not required mechanistically for Atg8 conjugation, but its presence increases the efficiency of this process and may dictate the site of conjugation ([@bib7]; [@bib23]). Thus, the presence of Atg16 may partially mask the Atg8 lipidation defects of the Atg5^E141D^ mutant, and this may explain why the E122D/E141D mutation induces a hypomorphic rather than a complete null phenotype.

ATG5^E122D^ fails to complement the ataxic phenotype of *Atg5*-null flies {#s2-6}
-------------------------------------------------------------------------

To further characterize the effect of the E122D mutation on the development of ataxia, we generated *Drosophila melanogaster* knockouts for *Atg5* ([Figure 6A](#fig6){ref-type="fig"}), and reconstituted the *Atg5*-null mutant flies with transgenes expressing wild-type (WT) or E122D human ATG5 ([Figure 6B-D](#fig6){ref-type="fig"}). Unlike mouse models, *Atg5*-null flies are viable, although they exhibit severe mobility defects after adult eclosion as demonstrated by a negative geotaxis assay ([Figure 6E and I](#fig6){ref-type="fig"}, and [Video 1](#media1){ref-type="other"}), similar to *Atg7* null mutant flies ([@bib27]). These mobility defects were substantially restored by expression of ATG5^WT^ ([Figure 6F and I](#fig6){ref-type="fig"}, and [Video 2](#media2){ref-type="other"}), suggesting that the molecular function of ATG5 is conserved between human and *Drosophila*. However, *Atg5*-null mutant flies expressing ATG5^E122D^ were still defective in mobility although slightly better than *Atg5*-null controls ([Figure 6G--I](#fig6){ref-type="fig"}, and [Videos 3](#media3){ref-type="other"} and [4](#media4){ref-type="other"}), demonstrating again that ATG5 activity is compromised but not eliminated by the E122D mutation. ATG5^E122D^ was also inferior to ATG5^WT^ in suppressing Ref(2)P (fly p62/SQSTM1) accumulation ([Figure 6J and K](#fig6){ref-type="fig"}) and cell death ([Figure 6L and M](#fig6){ref-type="fig"}) in the brain of *Atg5*-null mutant flies.10.7554/eLife.12245.009Figure 6.Ataxic phenotype of *Atg5*-null flies is suppressed by human ATG5^WT^ but not by ATG5^E122D^.(**A**) Genomic organization of the *Atg5* locus and the *Atg5*-null mutant (*Atg5^5cc5^*)*. Atg5^5cc5^* mutants have a CRISPR-Cas9-mediated deletion in approximately 1.5 kb residues that eliminate more than 85% of Atg5-coding sequences including the translation start site. Open boxes, untranslated exons; closed boxes, protein-coding exons. Scale bar, relative length of 1 kb genomic span. (**B**) Schematic representation of how *ATG5* transgenic flies were made. Plasmid which can express wild-type or E122D-mutated human *ATG5* was inserted into an identical genomic location (the attP site) through phiC31-mediated recombination ([@bib3]; [@bib4]; [@bib57]). The scheme was adapted from a previous publication ([@bib28]). (**C**) Genetic scheme of how *ATG5* transgenes were placed into the *Atg5*-null mutant flies. *Atg5, UAS-ATG5* and *Tub-Gal4* loci are on the X-chromosome, second chromosome and third chromosome, respectively. (**D**) Whole flies of indicated genotypes were analyzed by IB. (**E** to **H**) Photographs of the vials containing 2-week-old adult male flies of indicated genotypes taken at 3 sec after negative geotaxis induction: (**E**) *Atg5*-null flies exhibit severely impaired mobility. (**F**) Ataxic phenotype of *Atg5*-null flies is complemented by human ATG5^WT^ expression. (**G** and **H**) Human ATG5^E122D^ is less capable than human ATG5^WT^ in suppressing the fly ataxia phenotype. (**I**) Quantification of the climbing speeds of 2-week-old adult male flies (n≥20) of the indicated genotype. Climbing speed is presented as mean ± standard deviation (n=5). P values were calculated using the Student's t test (\*\*\*p\<0.001). (**J**) *Drosophila* heads from two-weeks-old flies of the indicated genotypes were analyzed by IB. (**K**) Ref(2)P \[p62\] is an autophagy substrate. Relative protein expression was measured by densitometry and presented in a bar graph (mean ± standard error; n=4). (**L**) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) of *Drosophila* brain (middle layer of the medial compartment). (**M**) TUNEL-positive cells per field were quantified and presented in a bar graph (mean ± standard error; n≥5). K and M: *P* values were calculated using the Student's t test (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.12245.009](10.7554/eLife.12245.009)Video 1.Climbing assay in 2 weeks-old wild-type flies (left) and *Atg5*-null flies (right).**DOI:** [http://dx.doi.org/10.7554/eLife.12245.010](10.7554/eLife.12245.010)10.7554/eLife.12245.010Video 2.Climbing assay in 2 weeks-old *Atg5*-null flies (left) and *Atg5*-null flies expressing *ATG5*^WT^ (right).**DOI:** [http://dx.doi.org/10.7554/eLife.12245.011](10.7554/eLife.12245.011)10.7554/eLife.12245.011Video 3.Climbing assay in 2 weeks-old *Atg5*-null flies (left) and *Atg5*-null flies expressing *ATG5*^E122D^ (right).**DOI:** [http://dx.doi.org/10.7554/eLife.12245.012](10.7554/eLife.12245.012)10.7554/eLife.12245.012Video 4.Climbing assay in 2 weeks-old *Atg5*-null flies expressing *ATG5*^WT^ (left) or *ATG5*^E122D^ (right).**DOI:** [http://dx.doi.org/10.7554/eLife.12245.013](10.7554/eLife.12245.013)10.7554/eLife.12245.013

Discussion {#s3}
==========

In summary, we demonstrate that the homozygous E122D mutation of ATG5, a unique mutation found in two human subjects with ataxia, results in reduced conjugation to ATG12 and in an overall decrease in autophagy activity. The homologous mutation in yeast also interferes with autophagy, and the ataxia phenotype was replicated in a fly model. Based on these results we propose that this *ATG5* mutation, and the consequent disruption in autophagy activity, is the cause of the ataxic phenotype and disturbance of the cerebellum in the affected siblings. This hypothesis is in agreement with previously characterized mouse models, in which neuron-specific knockout of *Atg5* results in ataxia-like phenotypes ([@bib24]; [@bib44]). By contrast, mice with complete knockout of *Atg5* die shortly after birth, demonstrating that autophagy is essential for mammalian survival ([@bib33]). Our results indicate that E122D is a partial loss-of-function allele that impairs but does not completely abolish ATG5 activity. Although the overall structure of the E122D mutant ATG5 superimposes well with the wild-type protein, the mutation causes a striking decrease in the level of ATG12--ATG5 conjugate that is formed when the C terminus of ATG12 is covalently linked to Lys130 of ATG5. We speculate that the E122D mutation causes subtle changes in the conformational dynamics that propagate to Lys130, which is less than 10 Å away, resulting in less ATG12--ATG5, which in turn leads to reduced LC3/Atg8 conjugation.

In neurons, which are among the cells most dependent on autophagy for tissue homeostasis ([@bib6]), the residual function of the E122D allele is inadequate, resulting in predominantly neurological symptoms in the two patients. Since homozygous mutations with complete loss-of-function have not been reported, we predict that individuals carrying such mutations, similar to *Atg5*-null mice ([@bib33]), might not be viable.

Autophagy is quickly gaining importance for its roles in preventing neurodegeneration. *WDR45* is a redundant, non-core autophagy gene, one of four mammalian homologs to Atg18, and mutations in *WDR45* cause SENDA, static encephalopathy of childhood with neurodegeneration in adulthood ([@bib22]; [@bib51]). Autophagy appears to be critical in ataxia, whether mutant proteins evade autophagy processes or normal autophagy is disrupted. Several ataxias are attributed to intranuclear or cytoplasmic aggregation of mutant proteins within the cell ([@bib37]). These protein aggregates, in humans and in mouse models, not only evade autophagic sequestration but may even inhibit autophagy ([@bib2]), or lead to reduction in autophagy available for other proteins due to saturation. Assessment of autophagy in patient cells may be used to refine and identify the genetic cause of a patient's ataxia.

Further discovery of the role of autophagy in neurodegenerative diseases should be used to investigate therapies targeted at the autophagy process. Many drugs enhance autophagy and their effects on a multitude of neurodegenerative diseases have been studied ([@bib54]). Recently more studies have been conducted assessing the value of autophagy enhancers in ataxia models and patients. Induction of autophagy through administration of Temsirolimus, a rapamycin ester, and lentiviral overexpression of BECN1 in SCA3 model mice increase autophagy and the clearance of mutant protein aggregates, and reduce the ataxic phenotype ([@bib39]; [@bib43]). In a single patient trial, trehalose treatment of patient fibroblasts increased autophagy and alleviated cellular pathogenic features by improving mitochondrial morphology and reducing free radicals in the cell ([@bib8]; [@bib53]). Trehalose also showed success in trials involving models of SCA17 ([@bib9]). Lithium, another inducer of autophagy, improved symptoms in a SCA1 mouse model ([@bib58]), but did not slow or reduce symptoms in a treatment trial in SCA2 patients ([@bib50]). An autophagy enhancer may be an appropriate treatment to test in the presented subjects, as autophagic flux is attenuated, but not completely abrogated, by the *ATG5^E122D/E122D^* mutation.

This study's finding of the pathogenic human E122D mutation in *ATG5*, a gene encoding part of the autophagy-controlling core machinery, is important and novel, but consistent with reports of neurodegenerative disorders in other autophagy-related genes ([@bib17]). Our results suggest that other mutations in this and other *ATG* genes, which impair but do not completely abolish autophagy, may result in similar forms of ataxia, intellectual disability and developmental delay. This study exemplifies the utility of exome sequencing in the identification of rare disease-causing variants, and supports the role of impaired autophagy in neurodegenerative disease. In addition, we demonstrate the utility of a combined genetic, biochemical and cell biological analysis in multiple model systems to elucidate the underlying pathogenic mechanism of rare human diseases.

Materials and methods {#s4}
=====================

Subjects {#s4-1}
--------

Study protocols including written informed consents have been approved by the University of Michigan Institutional Review Board and the Boğaziçi University Institutional Review Board for Research with Human Participants. Two Turkish brothers, ages 5 and 7 in 2004, presented with ataxia and developmental delay, as previously described ([@bib59]). Parents were initially reported to be unrelated, but recently suggested they might be remotely related. Both patients were delayed in walking, had truncal ataxia and dysmetria, nystagmus, and lower IQ (68 and 70). MRI revealed cerebellar hypoplasia. Follow-up examinations showed no progression of symptoms.

Genetic analysis {#s4-2}
----------------

DNA was isolated from peripheral whole blood using the Qiagen (Germantown, MD) Gentra Puregene isolation kit. Linkage analysis was performed using the genotype data generated with Illumina HumanOmniExpress-24 chip for the mother and the four sibs. The Allegro module ([@bib20]) of easyLINKAGE software was used, assuming autosomal recessive inheritance and parents as third cousins. No deletion or duplications common to just the two affected brothers were detected using cnvPartition plug-in in Illumina Genome Studio v.1.02 software.

Exome sequencing was performed independently twice on one subject. Capture for whole exome sequencing was performed with NimbleGen SeqCap EZ Exome Library v1.0 kit (Roche, Indianapolis, IN). Captured regions were sequenced with Illumina HiSeq2000 instruments. Variants were filtered to remove common variants based on 1000 Genomes, Exome Sequencing Project, and Exome Aggregation Consortium databases, variants outside of identified linkage regions, variants not expected to change protein coding, and variants not following a recessive model of inheritance ([@bib15]; [@bib19]; [@bib42]).

PCR followed by Sanger sequencing was performed to validate the variant identified through exome sequencing and test for segregation within the family. The variant of interest was further examined in two separate collections of a total of 500 Turkish samples, and found absent.

Lymphoblast cell culture {#s4-3}
------------------------

Lymphoblastoid cell lines (LCL) of both subjects were generated from heparinized whole blood samples and cultured as described ([@bib13]). As they are made in house and cultured briefly, mycoplasma contamination risk is minimized.

Protein co-expression and affinity purification from insect cells {#s4-4}
-----------------------------------------------------------------

We used a baculovirus/insect cell expression system to examine formation of the human ATG12--ATG5 conjugate in a heterologous system described previously ([@bib49]). Hi5 insect cells (Invitrogen, Carlsbad, CA) were infected with baculoviruses expressing human ATG7, ATG10, a GST-tagged version of ATG12 (residues 53--140, corresponding to the ubiquitin-like domain) and a His-tagged version of either ATG5^WT^ or ATG5^E122D^. Three days post infection, lysates were subjected to glutathione affinity chromatography, and the GST-ATG12--His-ATG5 conjugate was detected by SDS-PAGE followed by Coomassie Blue staining. To confirm that the baculoviruses produce protein, Hi5 cells were coinfected with baculoviruses expressing the His-tagged WT and mutant versions of ATG5 and the N-terminal domain of ATG16L1 (residues 1--69, as an MBP fusion). At three days post infection, lysates were subjected to nickel affinity purification. The ATG5-ATG16L1 complex formation was detected by SDS-PAGE and Coomassie Blue staining.

Crystallization and structure determination {#s4-5}
-------------------------------------------

The complex containing ATG5^E122D^ and the N-terminal domain of ATG16L1 (residues 1--69) was expressed in Hi5 insect cells, and purified by nickel affinity, ion exchange, and size exclusion chromatography into a final buffer of 20 mM Tris, pH 8.5, 50 mM NaCl, 10 mM DTT. The complex was concentrated to 18.5 mg/ml, aliquoted, flash-frozen and stored at -80°C until further use. Crystals were grown by the hanging drop vapor diffusion method by mixing purified protein 1:1 with reservoir solutions of 37.5 mM MES, pH 5.2--5.8, 0.2 M sodium tartrate, and 11--13% polyethylene glycol 3350. Final crystals were obtained by micro-seeding with reservoir solution of 40 mM MES, pH 5.5, 0.2 M sodium tartrate, 8.5% PEG3350, 10 mM DTT. Crystals were cryoprotected in reservoir solution supplemented with 25% xylitol, and flash frozen in liquid nitrogen prior to data collection. Diffraction data were processed with XDS. The structure was determined by molecular replacement using Phaser ([@bib38]) with the structure of the WT ATG5-ATG16L1 (1--69) (PDB: 4TQ0) complex as a search model ([@bib29]). Model construction and rebuilding were performed using Coot ([@bib14]). The structure was refined using Phenix ([@bib1]). Diffraction data and refinement statistics are provided in [Table 1](#tbl1){ref-type="table"}.

Immunoblotting {#s4-6}
--------------

Cells or tissues were lysed in cell lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na~3~VO~4~, 1% Triton X-100) or RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% NP-40, 0.1% SDS) containing protease inhibitor cocktail (Roche). After being clarified with centrifugation, lysates were boiled in SDS sample buffer, separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and probed with the indicated antibodies. ATG5 (12994), LC3 (3868) and SQSTM1/p62 (5114) antibodies were purchased from Cell Signaling Technology. Hemagglutinin (HA, 3F10) antibody was from Roche. Actin (JLA20) and tubulin (T5168) antibodies were from Developmental Studies Hybridoma Bank and Sigma, respectively. Ref(2)P antibody was previously described ([@bib48]).

HEK293 cell culture {#s4-7}
-------------------

Wild-type human ATG5-coding sequence was from Addgene \#24922 (deposited by Dr. Toren Finkel) ([@bib34]). The E122D mutation was introduced into *ATG5* by PCR-based site-directed mutagenesis. ATG5^WT^ and ATG5^E122D^ were cloned into the plasmid pLU-CMV-Flag. The HA-ATG12-expressing plasmid was from Addgene \#22950 (deposited by Dr. Noboru Mizushima) ([@bib41]). HEK293 cells (the 293 A substrain from Invitrogen, tested negative for mycoplasma by PCR) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS) and penicillin/streptomycin at 37°C in 5% CO2. For transient expression of proteins, HEK293 cells were transfected with purified plasmid constructs and polyethylenimine (PEI, Sigma) as previously described ([@bib25]). Cells were harvested 24 hr after transfection for immunoblot analyses.

Yeast model {#s4-8}
-----------

*Saccharomyces cerevisiae* strain WLY176 was used to generate an *ATG5* knockout strain (*atg5∆*) as previously described ([@bib21]). The MKO strain YCY137 (SEY6210 *atg1∆, 2∆, 4∆, 5∆, 6∆, 7∆, 8∆, 9∆, 10∆, 11∆, 12∆, 13∆, 14∆, 16∆, 17∆, 18∆, 19∆, 20∆, 21∆, 23∆, 24∆, 27∆, 29∆*) ([@bib7]), was used for in vivo reconstitution of Atg8 conjugation. Site-directed mutagenesis was performed to generate *ATG5* amplicons with the E141D mutation as previously described ([@bib36]). A pRS406 empty plasmid was digested with Spel and SalI, and then ligated with a DNA fragment encoding either wild-type or mutant Atg5-PA. *atg5∆* was transformed with an empty pRS406 vector, or plasmids encoding Atg5-PA WT or Atg5-PA E141D. Wild-type WLY176 colonies were transformed with empty pRS406 vector as a control. Colonies were grown on SMD-URA medium and starved in nitrogen-deficient medium. Pho8Δ60 and western blot analyses were performed as described previously ([@bib45]; [@bib55]). Quantification was performed using ImageJ software. The pATG8*∆*R-ATG7-ATG10(414), pATG5(WT)-HA-ATG12(416) and pATG5(WT)-HA-ATG12-ATG16(416) plasmids were described previously ([@bib7]). The pATG5(E141D)-HA-ATG12(416) and pATG5(E141D)-HA-ATG12-ATG16(416) plasmids were made by site-directed mutagenesis based on the wild-type constructs.

*Drosophila* genetics {#s4-9}
---------------------

*Atg5*-null *Drosophila* flies (*Atg5^5cc5^*) were generated by CRISPR-Cas9-mediated genome editing, using a double gRNA approach, both targeting the same gene, as described ([@bib32]). The *Atg5^5cc5^* mutant was recovered by screening viable candidate lines for accumulation of the specific autophagy cargo Ref(2)P using western blots, followed by PCR and sequencing. *Atg5^5cc5^* mutants have a deletion in X:7,322,242--7,323,717 residues (*Drosophila melanogaster* R6.06), which deletes five out of six exons of the *Atg5* gene, eliminating more than 85% of protein-coding sequences including the translation start site ([Figure 6A](#fig6){ref-type="fig"}). The PhiC31 integrase-mediated site-specific transformation method was used to express human ATG5^WT^ and ATG5^E122D^ from an identical genomic locus ([@bib3]; [@bib4]; [@bib57]). In brief, flag-tagged ATG5^WT^ and ATG5^E122D^ were cloned into a pUAST-attB vector ([@bib4]) and fully sequenced. pUAST-attB-ATG5^WT^ and pUAST-attB-ATG5^E122D^ were microinjected into *y^1^ M{vas-int.Dm}ZH-2A w^\*^; M{3xP3-RFP.attP}ZH-51D* flies and stable transformants were isolated by the presence of the *mini-white^+^* marker ([Figure 6B](#fig6){ref-type="fig"}). The UAS-ATG5^WT^ or UAS-ATG5^E122D^ transgenes were crossed with a double balancer strain (*Bl/CyO; TM2/TM6B*) and then with +/*CyO; Tub-Gal4/TM2* to be constructed as stable *Tub\>ATG5* lines (*UAS-ATG5/UAS-ATG5; Tub-Gal4/TM6B*). The *Tub\>ATG5* male flies were crossed with *Atg5^5cc5^/FM7* female flies to generate *Atg5*-null flies expressing human *ATG5* transgenes. Climbing assays and TUNEL staining were performed as previously described ([@bib30]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Mutation in *ATG5* Reduces Autophagy and Leads to ataxia with Developmental Delay\" for consideration in *eLife*. Your article has been favorably evaluated by a Senior Editor and three reviewers, one of whom, Noboru Mizushima, is a member of our Board of Reviewing Editors, and another is Joan Steffan.

The reviewers have discussed the reviews with one another and the reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors identify a novel missense mutation in the *ATG5* gene in two ataxia patients. A partial reduction of the autophagic activity is observed in patients\' cells as well as in yeast and fly having corresponding mutations. Locomotor abnormalities are also reproduced in fly mutants. This is the first report of a human disease having a pathogenic mutation in non-redundant core *ATG* genes.

Essential revisions:

Overall the data support the authors\' conclusion. This is an important and timely study. However, as the authors performed exome sequencing of only one pair of patients, they should be careful to conclude that this is indeed a causative mutation.

1\) To convince that the mutation in ATG5 is indeed \"damaging\", it is important to clearly show that the autophagic activity is reduced in mutant cells. However, the reduction is relatively small and even not convincing in some experiments. For example, in the bottom panel of [Figure 3B](#fig3){ref-type="fig"}, bafilomycin A1-induced increase in the SQSTM1 level seems to be larger in ATG5 mutant cells compared to WT cells, suggesting that autophagic flux is not affected. On the other hand, the LC3-II turnover assay in [Figure 3C](#fig3){ref-type="fig"} clearly shows that the autophagic flux is reduced in ATG5 mutant cells. In [Figure 3B](#fig3){ref-type="fig"}, rapamycin decreases the level of SQSTM1 in sample H but not in sample I (both are from unaffected individuals), making the evaluation of the patients\' samples difficult. These inconsistencies need to be clarified. It would be recommended to include SQSTM1 blots and rapamycin (Torin 1 may be better) treatment in panel C. Including \"rescued ATG5^E122D^ cells\" expressing wild-type ATG5 would also strengthen the conclusion.

2\) Along the same line, the autophagic activity is significantly reduced in mutant yeast cells at 3 h after starvation in Figure 5AB, but it is normal at 2-4 h and apparently reduced only at 6 h in [Figure 5C](#fig5){ref-type="fig"}. This should be clarified. The authors use only the Pho8Δ60 assay to evaluate autophagy in yeast. It is recommended to use multiple methods to measure the autophagic activity (e.g., GFP-ATG8 cleavage, ATG8-PE formation, etc.).
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Author response

Essential revisions: Overall the data support the authors\' conclusion. This is an important and timely study. However, as the authors performed exome sequencing of only one pair of patients, they should be careful to conclude that this is indeed a causative mutation. 1) To convince that the mutation in ATG5 is indeed \"damaging\", it is important to clearly show that the autophagic activity is reduced in mutant cells. However, the reduction is relatively small and even not convincing in some experiments. For example, in the bottom panel of [Figure 3B](#fig3){ref-type="fig"}, bafilomycin A1-induced increase in the SQSTM1 level seems to be larger in ATG5 mutant cells compared to WT cells, suggesting that autophagic flux is not affected. On the other hand, the LC3-II turnover assay in [Figure 3C](#fig3){ref-type="fig"} clearly shows that the autophagic flux is reduced in ATG5 mutant cells. In [Figure 3B](#fig3){ref-type="fig"}, rapamycin decreases the level of SQSTM1 in sample H but not in sample I (both are from unaffected individuals), making the evaluation of the patients\' samples difficult. These inconsistencies need to be clarified. It would be recommended to include SQSTM1 blots and rapamycin (Torin 1 may be better) treatment in panel C. Including \"rescued ATG5^E122D^ cells\" expressing wild-type ATG5 would also strengthen the conclusion.

We agree with the reviewers that the data presented in the former [Figure 3](#fig3){ref-type="fig"} were confusing because of inconsistencies in the magnitude of autophagy defects. This is mainly due to the fact that the E122D mutation does not completely nullify the functionality of ATG5; therefore, a more careful experimental design was necessary.

In the former [Figure 3B](#fig3){ref-type="fig"}, we subjected the cells to overnight treatments of rapamycin, thapsigargin and bafilomycin A~1~, which may induce secondary non-specific effects. For example, in addition to the autophagic mechanism, the level of SQSTM1/p62 is also controlled by a transcriptional mechanism (J Biol Chem. 2010 285:22576-91), which may be non-specifically altered by prolonged treatments with these drugs. Therefore, the experiment represented by the former [Figure 3B](#fig3){ref-type="fig"} was re-evaluated as a poor design, which would make the evaluation of patients' samples difficult. Correspondingly, we have removed this figure panel and have instead performed the reviewers' suggested experiment.

[Figure 3C](#fig3){ref-type="fig"} in the former manuscript (now [Figure 3B](#fig3){ref-type="fig"} in the revised manuscript) is a better designed experiment, and clearly shows that the autophagic flux is reduced in ATG5 mutant cells. As the reviewers recommended, we have included SQSTM1 blots and Torin 1 treatment in this set of data. The new results presented in [Figure 3C](#fig3){ref-type="fig"} of the revised manuscript convincingly demonstrate that (1) ATG12--ATG5 conjugates are reduced in E122D homozygotic patient cells, (2) SQSTM1/p62 is upregulated in these patient cells and (3) bafilomycin A~1~-induced LC3-II accumulation, which indicates autophagic flux, is attenuated in the patients' cells, regardless of Torin 1 treatment. We think that these new experiments clarify that autophagic flux is indeed attenuated in ATG5^E122D^ mutant patient cells.

We also agree that rescuing patient cells with wild-type ATG5 would lend additional support concerning the disease-causing role of the E122D mutation. However, this experiment is challenging because of the extremely low transduction efficiency for LCL cells. These cells are not amenable to conventional transfection methods (PEI or liposomes). Even lentiviruses, which can transduce \~99% of monolayer cells such as HeLa, NIH3T3 and HepG2, were only able to transduce less than 5% of LCL suspensions (based on GFP expression). Though direct rescue of patient cells was impossible due to these technical difficulties, we have shown that human ATG5^WT^, but not ATG5^E122D^, is effective in restoring autophagy defects and neurodegenerative phenotypes exhibited in Atg5-knockout flies ([Figure 6](#fig6){ref-type="fig"}). We have also demonstrated that ATG5^E122D^ is biochemically defective in ATG12 conjugation in both cell culture and structural biology experiments ([Figure 4](#fig4){ref-type="fig"}). Therefore, the data strongly indicate that ATG5^E122D^ is functionally inferior to ATG5^WT^ in mediating autophagy, results that are also supported by the studies in yeast (see below).

*2) Along the same line, the autophagic activity is significantly reduced in mutant yeast cells at 3 h after starvation in Figure 5AB, but it is normal at 2-4 h and apparently reduced only at 6 h in [Figure 5C](#fig5){ref-type="fig"}. This should be clarified. The authors use only the Pho8Δ60 assay to evaluate autophagy in yeast. It is recommended to use multiple methods to measure the autophagic activity (e.g., GFP-ATG8 cleavage, ATG8-PE formation, etc*.).

Again, the subtle variations between experimental results was the result of the hypomorphic nature of the E122D (E141D in yeast) mutation. By repeating the experiment ([Figure 5B](#fig5){ref-type="fig"} in the revised manuscript) using multiple time points, we have shown that the difference in autophagic activity, measured by the Pho8Δ60 assay, is statistically significant in later time points (4-6 h). Although not statistically significant, there is also a clear trend that the E141D mutation leads to a decreased Pho8Δ60 activity at earlier time points (1-3 h) as well. Considering that the Pho8Δ60 activity reflects a cumulative result of autophagic flux, it is actually not surprising that a longer incubation period would lead to a stronger statistical significance. Importantly, the same results are seen when we use strains with an integrated Atg5^E141D^ mutation ([Figure 5C](#fig5){ref-type="fig"}).

Given the hypomorphic nature of the mutation, we agree that it is better to use multiple methods to measure the autophagic activity. Therefore, we performed GFP-ATG8 cleavage and ATG8--PE formation assays, as the reviewers recommended. In the GFP-ATG8 cleavage assay (J Biol Chem. 2004 279:29889-94), we have shown that the generation of free GFP, which is indicative of autophagic activity, is slightly but significantly attenuated in a yeast strain whose Atg5 was substituted with Atg5^E141D^ ([Figure 5A](#fig5){ref-type="fig"} in the revised manuscript).

We have also performed the Atg8‒PE formation assays. As shown by the ratio of Atg8--PE:total Atg8, cells expressing Atg5^E141D^ displayed a decrease in Atg8--PE conjugation compared to cells expressing Atg5^WT^ ([Figure 5D](#fig5){ref-type="fig"} in the revised manuscript). We also extended this analysis by using the in vivo reconstitution of Atg8--PE conjugation as described previously (J Cell Biol. 2008 182:703-13). In brief, we used a multiple-knockout (MKO) strain in which 23 *ATG* genes are deleted to examine Atg8 lipidation when expressing only the E1, E2 and E3-like conjugation enzymes. Atg8∆R that lacks the C-terminal arginine was used in the assay to bypass the initial activation step mediated by Atg4; due to the absence of Atg4, there is no cleavage of Atg8--PE from the membrane, resulting in stabilization of this form of the protein. We found that the Atg5^E141D^ mutant was strongly defective in Atg8--PE conjugation compared to the cells with Atg5^WT^ when Atg16 was not present ([Figure 5E](#fig5){ref-type="fig"} in the revised manuscript). As explained in the revised manuscript, Atg16 is not required mechanistically for Atg8 conjugation, but its presence increases the efficiency of this process and may dictate the site of conjugation (J Cell Biol. 2008 182:703-13). Thus, the presence of Atg16 (as in [Figure 5D](#fig5){ref-type="fig"}) may partially mask the Atg8 lipidation defects of the Atg5^E141D^ mutant, and this would be at least one reason as to why the E122D/E141D mutation induces a hypomorphic rather than a complete null phenotype in both humans and model organisms.

Collectively, these new experiments performed in both yeast and mammalian cells, together with formerly included results from *Drosophila*, strongly support our conclusion that the E122D mutation is indeed damaging ATG5 function in mediating autophagy.

[^1]: These authors contributed equally to this work.
